Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

35.14 -0.17 (-0.48%)
Streaming Delayed Price Updated: 10:00 AM EDT, Mar 23, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Roche Joins Hand With Lilly To Improve Early Diagnosis Of Alzheimer's Disease
 
Via Benzinga
New Four Year Data For Roche's Evrysdi Reinforces Long-Term Efficacy, Safety Profile In Muscular Atrophy Patients
 
Via Benzinga
Is Roche a Buy Now?
Roche focuses on the long-term. 
Via The Motley Fool
New Four-Year Data for Genentech’s Evrysdi Reinforce Long-Term Efficacy and Safety Profile in Some of the Most Severely Affected People With Types 2 and 3 Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
Sarepta Plunges As FDA Takes Surprise Turn; AdComm Meeting Set For Duchenne Gene Therapy
 
Via Benzinga
Roche Introduces Test To Detect Contagious XBB.1.5 Omicron Sub-Variant
 
Via Benzinga
Daily Stock Analysis: Roche Holding AG
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was... 
Via Talk Markets
Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 15, 2023 – USA News Group – According to a 2022 study of more than 6 million patients 65 and older, the risk factor for... 
Via FinancialNewsMedia
Exposures COVID-19
FDA Advisory Committee Votes in Favor of the Clinical Benefit of Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma
From Genentech
Via Business Wire
FDA Casts Doubts Over Roche's Polivy Label Expansion For Untreated Lymphoma Setting
 
Via Benzinga
The Top 7 Growth Stocks in Biotech
The biotech sector always houses a great selection of growth stocks that can grow rapidly and reward investors over the long-term. 
Via InvestorPlace
Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo
 
Via Benzinga
Why Sarepta Therapeutics' Shares Rose 23.4% This Week
The company's latest Duchenne muscular dystrophy gene therapy may have an accelerated approval. 
Via The Motley Fool
3 Best Growth Stocks to Buy In March
These three red-hot growth stocks have more room to run. 
Via The Motley Fool
Blueprint Medicines Highlights Detailed Data From Lead Product In Blood Cancer Patients
 
Via Benzinga
Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines
 
Via Benzinga
Infinity Pharmaceuticals Announce Merger Agreement With MEI Pharma, Share Plunge
 
Via Benzinga
Apellis Surges To Four-Month High — Sending Rival Iveric Tumbling — On A First-Ever Approval
Apellis is soon to launch its newest drug, Syfovre, for geographic atrophy patients. 
Via Investor's Business Daily
Biogen Beats Q4 Earnings & Sales Estimates, Stock Up
Biogen reported fourth-quarter 2022 adjusted earnings per share (EPS) of $4.05. 
Via Talk Markets
New Data Shows Roche's Vabysmo Improves Vision, Retinal Fluid In Retinal Disorder
 
Via Benzinga
New Phase III Data Show Genentech’s Vabysmo Rapidly Improved Vision and Reduced Retinal Fluid in People With Retinal Vein Occlusion (RVO)
From Genentech
Via Business Wire
Roche Touts Positive Crovalimab Data From Late-Stage Study In Rare Blood Condition
 
Via Benzinga
Genentech Announces Positive Data From Global Phase III Program for Crovalimab in PNH, a Rare, Life-Threatening Blood Condition
From Genentech
Via Business Wire
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
The company that remains still has a large pipeline of non-migraine assets. 
Via Investor's Business Daily
Roche Flags Lower 2023 Sales On Declining Demand For COVID-19 Treatment, Diagnostics
 
Via Benzinga
Genentech's Tecentriq Plus Avastin Combo Cuts Risk of Cancer Returning In Early-Stage Liver Cancer
 
Via Benzinga
Genentech’s Tecentriq Plus Avastin Is the First Treatment Combination to Reduce the Risk of Cancer Returning in People With Certain Types of Early-Stage Liver Cancer in a Phase III Trial
From Genentech
Via Business Wire
Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December
On December 14th, the Federal Reserve hiked its key interest rate by 50 basis points. This was the first deceleration in rate hike increases in 2022; between March and November 2022, the interest rate... 
Via Benzinga
Europe Approves Xofluza, Roche's Revolutionary Influenza Antiviral with New Mechanism
 
Via Benzinga
Biotech Giant Regeneron Hit As Eylea Gives Ground To Avastin
Regeneron Pharmaceuticals says sales of linchpin Eylea drug have been negatively impacted rival drug Avastin. REGN stock plunged on the news. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.